Steven Cohen's Point72 Asset Management Acquires New Stake in Sagimet Biosciences Inc [Yahoo! Finance]
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: Yahoo! Finance
On February 2, 2024, Point72 Asset Management, led by renowned investor Steven Cohen Trades Portfolio ), executed a significant buy action, acquiring 1,612,639 shares in Sagimet Biosciences Inc ( NASDAQ:SGMT ). This transaction marked a new holding for the firm, with the shares purchased at a price of $10.05 each. The addition of these shares to Point72's portfolio represents a 0.05% impact, with the firm now holding a 5.30% stake in Sagimet Biosciences Inc. Steven Cohen Trades Portfolio ) and Point72 Asset Management Steven A. Cohen stands as the Chairman and Chief Executive Officer of Point72, a substantial registered investment advisor with over 1,650 personnel. Cohen, who began his investing career at Gruntal & Co., later founded S.A.C. Capital Advisors in 1992, which transitioned into the Point72 Asset Management family office in 2014. The firm's investment philosophy centers on a long/short equity strategy, employing a fundamental bottom-up research process to inform macro
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024GlobeNewswire
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerGlobeNewswire
- Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $32.00 price target on the stock.MarketBeat
- Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]Seeking Alpha
SGMT
Sec Filings
- 5/8/24 - Form 4
- 5/8/24 - Form 3
- 5/6/24 - Form 8-K
- SGMT's page on the SEC website